• 1
    Stephenson RA. Prostate cancer trends in the era of prostate-specific antigen: an update of incidence, mortality, and clinical factors from the SEER database. Urol Clin North Am. 2002; 29: 173181.
  • 2
    Tannock IF, Osoba D, Stockler MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol. 1996; 14: 17561764.
  • 3
    Kornblith AB, Herndon JE, Zuckerman E, Godley PA, Savarese D, Vogelzang NJ; Cancer and Leukemia Group B (CALGB). The impact of docetaxel, estramustine, and low dose hydrocortisone on the quality of life of men with hormone refractory prostate cancer and their partners: a feasibility study. Ann Oncol. 2001; 12: 633641.
  • 4
    Small EJ, McMillan A, Meyer M, et al. Serum prostate-specific antigen decline as a marker of clinical outcome in hormone-refractory prostate cancer patients: association with progression-free survival, pain end points, and survival. J Clin Oncol. 2001; 19: 13041311.
  • 5
    Schmid HP, McNeal JE, Stamey TA. Observations on the doubling time of prostate cancer. Cancer. 1993; 71: 20312040.
  • 6
    Patel A, Dorey F, Franklin J, deKernion JB. Recurrence patterns after radical retropubic prostatectomy: clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen. J Urol. 1997; 158: 14411445.
  • 7
    Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999; 281: 15911597.
  • 8
    D'Amico AV, Cote K, Loffredo M, Renshaw AA, Schultz D. Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer. J Clin Oncol. 2002; 20: 45674573.
  • 9
    Akimoto S, Masai M, Akakura K, Shimazaki J. Tumor marker doubling time in patients with prostate cancer: determination of prostate-specific antigen and prostatic acid phosphatase doubling time. Eur Urol. 1995; 27: 207212.
  • 10
    Schmid HP, Maibach R, Bernhard J, et al. A phase II study of oral idarubicin as a treatment for metastatic hormone-refractory prostate cancer with special focus on prostate specific antigen doubling time. Cancer. 1997; 79: 17031709.
  • 11
    Akimoto S, Inomiya H, Akakura K, Shimazaki J, Ito H. Prognostic factors in patients with prostate cancer refractory to endocrine therapy: univariate and multivariate analyses including doubling times of prostate-specific antigen and prostatic acid phosphatase. Jpn J Clin Oncol. 1997; 27: 258262.
  • 12
    Schmid HP, Morant R, Bernhard J, Maibach R; Swiss Group for Clinical Cancer Research (SAKK). Prostate specific antigen doubling time as auxiliary end point in hormone refractory prostatic carcinoma. Eur Urol. 2003; 43: 2830.
  • 13
    Smith JA, Soloway MS, Young MJ. Complications of advanced prostate cancer. Urology. 1999; 54: 814.
  • 14
    Dowling RA, Carrasco CH, Babaian RJ. Percutaneous urinary diversion in patients with hormone-refractory prostate cancer. Urology. 1991; 37: 8991.
  • 15
    Esper P, Redman BG. Hormone refractory prostate cancer: supportive care, pain management, and quality of life in advanced prostate cancer. Urol Clin North Am. 1999; 26: 375389.
  • 16
    Turner SL, Gruenewald S, Spry N, Gebski V; Metastron Users Group. Less pain does equal better quality of life following strontium-89 therapy for metastatic prostate cancer. Br J Cancer. 2001; 84: 297302.
  • 17
    Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst. 2002; 94: 14581468.